Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the results from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab in severe asthma

Ticker(s): GSK

Who's the expert?

Institution: Columbia University Medical Center

Professor of Medicine at CUMC & Director of the Columbia University Gunnar Esiason Adult Cystic Fibrosis (CF) Program and the Asthma Research Program.
Manages 100 patients with non-CF bronchiectasis and 175 patients with cystic fibrosis.
Serves as Principal Investigator for numerous research projects in the areas of cystic fibrosis and asthma.

Interview Goal

On this call we will be looking at data from the SWIFT-1 and SWIFT-2 phase III clinical trials of depemokimab and discussing how depemokimab fits into the current treatment landscape for adults and adolescents with severe asthma with type 2 inflammation characterized by raised blood eosinophil count.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.